Literature DB >> 19336945

Sesquiterpenes from cultures of the basidiomycete Clitocybe conglobata and their 11 beta-hydroxysteroid dehydrogenase inhibitory activity.

Di Xu1, Yu Sheng, Zhong-Yu Zhou, Rong Liu, Ying Leng, Ji-Kai Liu.   

Abstract

A new drimane sesquiterpenoid, 3-keto-drimenol (1), were isolated from cultures of the basidiomycete Clitocybe conglobata together with 3beta-hydroxy-11-acetyldrimene (2), 3beta-hydroxydrimenol (3), 11,12-dihydroxydrimene (4), 3beta-hydroxy-11,12-O-isopropyldrimene (5), and 3beta,11,12-trihydroxydrimene (6). Their structures were established from MS and NMR experiments. Compounds 1, 3, and 6 showed inhibitory activities against two isozymes of 11 beta-hydroxysteroid dehydrogenases with IC(50) 1.7-8.0 microg/ml (human 11 beta-HSD1), 10.7-24.1 microg/ml (mouse 11 beta-HSD1); 177.0-220.0 microg/ml (human 11 beta-HSD2), 250.5-500.2 microg/ml (mouse 11 beta-HSD2), respectively, which catalyze the interconversion of active cortisol and inactive cortisone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336945     DOI: 10.1248/cpb.57.433

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

1.  Validation of the Antidiabetic and Hypolipidemic Effects of Clitocybe nuda by Assessment of Glucose Transporter 4 and Gluconeogenesis and AMPK Phosphorylation in Streptozotocin-Induced Mice.

Authors:  Chun-Ching Shih; Mei-Hsing Chen; Cheng-Hsiu Lin
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-03       Impact factor: 2.629

2.  Four New Sesquiterpenoids from Cultures of the Fungus Phellinidium sulphurascens.

Authors:  Zhen-Zhu Zhao; He-Ping Chen; Tao Feng; Zheng-Hui Li; Ze-Jun Dong; Ji-Kai Liu
Journal:  Nat Prod Bioprospect       Date:  2014-12-10

3.  Antidiabetic and Antihyperlipidemic Effects of Clitocybe nuda on Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.

Authors:  Mei-Hsing Chen; Cheng-Hsiu Lin; Chun-Ching Shih
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-16       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.